Recurrence morbidity of olfactory neuroblastoma

Katie Melder¹, Jess C Mace², Garret Choby³, Joao Paulo Almeida⁴, Pierre-Olivier Champagne⁵, Erik Chan⁶, Jeremy Ciporen⁷, Mark B Chaskes⁸, Juan Fernandez-Miranda⁹, Nicholas K Fung³, Paul Gardner¹⁰, Peter Hwang⁶, Keven Seung Yong Ji², Aristotelis Kalyvas¹¹, Keonho A Kong¹², Chirag Patel¹³, Zara Patel⁶, Maria Peris Celda¹⁴, Carlos D Pinheiro-Neto¹⁵, Carl Snyderman³, Brian D Thorp¹⁶, Jamie J Van Gompel^{14

15}, Georgios Zenonos¹⁰, Nathan T Zwagerman¹⁷, Olabisi Sanusi⁷, Eric W Wang³, Mathew Geltzeiler²

Affiliations

¹ Department of Otolaryngology-Head and Neck Surgery, Louisiana State University, New Orleans, Louisiana, USA.
² Department of Otolaryngology-Head and Neck Surgery, Oregon Health & Science University, Portland, Oregon, USA.
³ Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
⁴ Department of Neurological Surgery, Mayo Clinic, Jacksonville, Florida, USA.
⁵ Department of Neurological Surgery, Université Laval, Quebec, Quebec, Canada.
⁶ Department of Otolaryngology-Head and Neck Surgery, Stanford University, Palo Alto, California, USA.
⁷ Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA.
⁸ Department of Otolaryngology-Head & Neck Surgery, Northwell Health/Zucker School of Medicine, Hofstra University, New Hyde Park, New York, USA.
⁹ Department of Neurological Surgery, Stanford University, Palo Alto, California, USA.
¹⁰ Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
¹¹ Department of Neurological Surgery, University of Toronto, Toronto, Ontario, Canada.
¹² Department of Otolaryngology-Head & Neck Surgery, University of Mississippi Medical Center, Jackson, Mississippi, USA.
¹³ Department of Otolaryngology-Head and Neck Surgery, Loyola University, Maywood, Illinois, USA.
¹⁴ Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota, USA.
¹⁵ Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota, USA.
¹⁶ Department of Otolaryngology-Head and Neck Surgery, University of North Carolina, Chapel Hill, North Carolina, USA.
¹⁷ Department of Neurological Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

PMID: 38567900
DOI: 10.1002/alr.23351

Recurrence morbidity of olfactory neuroblastoma

Katie Melder et al. Int Forum Allergy Rhinol. 2024 Sep.

. 2024 Sep;14(9):1435-1445.

doi: 10.1002/alr.23351. Epub 2024 Apr 3.

Authors

Affiliations

¹ Department of Otolaryngology-Head and Neck Surgery, Louisiana State University, New Orleans, Louisiana, USA.
² Department of Otolaryngology-Head and Neck Surgery, Oregon Health & Science University, Portland, Oregon, USA.
³ Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
⁴ Department of Neurological Surgery, Mayo Clinic, Jacksonville, Florida, USA.
⁵ Department of Neurological Surgery, Université Laval, Quebec, Quebec, Canada.
⁶ Department of Otolaryngology-Head and Neck Surgery, Stanford University, Palo Alto, California, USA.
⁷ Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA.
⁸ Department of Otolaryngology-Head & Neck Surgery, Northwell Health/Zucker School of Medicine, Hofstra University, New Hyde Park, New York, USA.
⁹ Department of Neurological Surgery, Stanford University, Palo Alto, California, USA.
¹⁰ Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
¹¹ Department of Neurological Surgery, University of Toronto, Toronto, Ontario, Canada.
¹² Department of Otolaryngology-Head & Neck Surgery, University of Mississippi Medical Center, Jackson, Mississippi, USA.
¹³ Department of Otolaryngology-Head and Neck Surgery, Loyola University, Maywood, Illinois, USA.
¹⁴ Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota, USA.
¹⁵ Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota, USA.
¹⁶ Department of Otolaryngology-Head and Neck Surgery, University of North Carolina, Chapel Hill, North Carolina, USA.
¹⁷ Department of Neurological Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

PMID: 38567900
DOI: 10.1002/alr.23351

Abstract

Background: With modern treatment paradigms, olfactory neuroblastoma (ONB) has favorable overall survival (OS); however, the incidence of recurrence remains high. The primary aims of this study were to delineate the prognosis of recurrence of ONB and explore how recurrence subsites are associated with OS, disease-specific survival (DSS), and further recurrence.

Methods: A retrospective chart review of ONB cases from nine academic centers between 2005 and 2021 was completed. Tumor characteristics, recurrence subsites, timelines to recurrence, additional recurrences, and survival estimates were determined using descriptive and time-to-event analyses.

Results: A final cohort of 233 patients was identified, with 70 (30.0%) patients recurring within 50.4 (standard deviation ±40.9) months of diagnosis on average, consisting of local (50%), neck (36%), intracranial (9%), and distant (6%) recurrence. Compared with subjects without recurrence, patients with recurrence had significantly different primary American Joint Committee on Cancer T stage (p < 0.001), overall stage (p < 0.001), and modified Kadish scores (p < 0.001). Histopathology identified that dural involvement and positive margins were significantly greater in recurrent cases. First recurrence was significantly associated with worse 5-year DSS (hazard ratio = 5.62; p = 0.003), and subjects with neck or local recurrence had a significantly better DSS compared to intracranial or distant recurrence.

Conclusions: Recurrent cases of ONB have significantly different stages and preoperative imaging factors. Patients with local or neck recurrence, however, have better DSS than those with intracranial or distant recurrence, independent of initial tumor stage or Hyams grade. Identifying specific factors that confer an increased risk of recurrence and DSS is important for patient counseling in addition to surveillance planning.

Keywords: esthesioneuroblastoma; olfactory neuroblastoma; recurrence; sinonasal malignancy; skull base.

PubMed Disclaimer

References

REFERENCES

1. Faragalla H, Weinreb I. Olfactory neuroblastoma: a review and update. Adv Anat Pathol. 2009;16(5):322‐331.
1. Thompson LD. Olfactory neuroblastoma. Head Neck Pathol. 2009;3(3):252‐259.
1. Sjöstedt S, Jensen DH, Jakobsen KK, et al. Incidence and survival in sinonasal carcinoma: a Danish population‐based, nationwide study from 1980 to 2014. Acta Oncol. 2018;57(9):1152‐1158.
1. Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res. 1997;17(4A):2683‐2706.
1. Wang EW, Zanation AM, Gardner PA, et al. ICAR: endoscopic skull‐base surgery. Int Forum Allergy Rhinol. 2019;9(S3):S145‐S365.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Recurrence morbidity of olfactory neuroblastoma

Affiliations

Recurrence morbidity of olfactory neuroblastoma

Authors

Affiliations

Abstract

References

REFERENCES

MeSH terms

LinkOut - more resources

Full Text Sources

Medical